Transforming Biomanufacturing Operations

October 2, 2014

(The Scientist) – Now that synthetic biology (synbio) has become an official bio-buzzword, it is time to take a step back and ask, “What’s in it for biomanufacturing?” At least one expert is not shy about answering the question. “Synthetic biology’s most immediate potential commercial benefits will be in the biomanufacturing of therapeutic proteins and vaccines,” says Klaus Lindpaintner, M.D., chief science officer, analytical instruments at Thermo Fisher Scientific. “And more broadly, it will affect many areas of chemical engineering, specifically in petrochemicals and plastics, as well as environmental remediation, crop science, and animal breeding. There are almost no limits to the promise of synthetic biology.”